Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824159 | 0.90 | CSNK2A2 (0.44) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4723548 | 0.86 | ROCK1 (0.42) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4764052 | 0.86 | GRIK1 (0.43) | RAB9ASMN1; SMN2MEN1KMT2AGRIK1 | |
| SCHEMBL4721735 | 0.85 | FLT3 (0.51) | NPC1RAB9AMEN1KMT2AGRIK1 | |
| SCHEMBL4724126 | 0.85 | CNR1 (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4908646 | 0.83 | NTRK1 (0.41) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4724837 | 0.82 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1322467 | 0.82 | ALDH1A1 (0.55) | NPC1SMYD2 | |
| SCHEMBL4720639 | 0.80 | IKBKB (0.40) | MEN1KMT2AGRIK1 | |
| SCHEMBL4723103 | 0.79 | CNR1 (0.55) | RAB9ASMN1; SMN2MEN1KMT2AGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912988-B1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| EP-1912988-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017577-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | NPC1 3669/4885RAB9A 3036/4885SMN1; SMN2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.